It was recently announced that Singapore-based SCG Cell Therapy, and Germany-based Formycon, have entered into a collaboration and license agreement for the development and commercialisation of Covid-19 drug FYB207. Christy Ma, Chief Strategy Officer, SCG Cell Therapy shares SCG’s recent collaboration with Germany-based Formycon for the development and commercialisation of Covid-19 drug FYB207, and how it differs from other experimental antiviral pills made by their competitors.

See omnystudio.com/listener for privacy information.